Sonal Tonapi
About Sonal Tonapi
Sonal Tonapi serves as the Manager of Aptamer Discovery at Nautilus Biotechnology, where she has worked since 2021. With a strong background in oncology and cancer biology, she has held various roles in research and development across academic and industry settings.
Work at Nautilus Biotechnology
Sonal Tonapi has been employed at Nautilus Biotechnology since 2021, currently holding the position of Manager Aptamer Discovery. In this role, she leads a team that qualifies probes for the Nautilus Proteome Analysis Platform. Prior to her current role, she served as Aptamer Discovery Lead for six months in 2021 and as Senior Scientist from 2019 to 2021. Her work at Nautilus emphasizes her expertise in aptamer discovery and development.
Education and Expertise
Sonal Tonapi earned her Doctor of Philosophy (PhD) in Oncology and Cancer Biology from the University of Texas Health Science Center at San Antonio, where she studied from 2010 to 2015. She also holds a Master of Science (M.S.) in Biochemistry and Molecular Biology from Georgetown University, completed in 2010, and a Bachelor of Science (B.Sc.) in Chemistry from the University of Pune, obtained in 2008. Her educational background supports her expertise in designing experimental strategies for drug target identification.
Background
Sonal Tonapi has a diverse professional background that includes significant roles in both academic and industry settings. She worked as a Graduate Research Assistant at the University of Texas Health Science Center San Antonio from 2010 to 2015. Following her graduate studies, she served as a Postdoctoral Researcher at Caris Life Sciences from 2015 to 2018 and as a Research Scientist I at the same organization for five months in 2018. Additionally, she has experience as a Research Scientist at Nautilus Biotechnology.
Achievements
Throughout her career, Sonal Tonapi has directed multi-disciplinary and collaborative projects, showcasing her ability to work effectively in diverse teams. She possesses extensive hands-on experience in non-invasive, unbiased disease profiling, which has contributed to her roles in aptamer discovery and drug target identification. Her leadership at Nautilus Biotechnology highlights her commitment to advancing proteomic analysis.